Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Roquefort Investments PLC ( (GB:ROQ) ) has shared an announcement.
Roquefort Therapeutics has announced an extension of the deadline for completing the sale of its subsidiary, Lyramid Pty Ltd, to Pleiades Pharma Limited. The extension, from June 30 to August 31, 2025, is due to delays in Pleiades’ fundraising efforts in the UAE, affected by geopolitical events. Upon completion, Roquefort will receive shares in Pleiades and potentially up to $2 million in cash. The company plans to incorporate a new equity holding company to distribute Pleiades shares to its existing shareholders, aiming to benefit them from this transaction while pursuing further acquisitions in clinical-stage assets or revenue-generating life science businesses.
More about Roquefort Investments PLC
Roquefort Therapeutics PLC is a biotech company listed on the London Stock Exchange, focusing on developing first-in-class drugs in the high-value immunology and oncology markets. The company’s portfolio includes five novel patent-protected pre-clinical anti-cancer and immunology assets.
Average Trading Volume: 1,106,995
Technical Sentiment Signal: Sell
Current Market Cap: £2.13M
For an in-depth examination of ROQ stock, go to TipRanks’ Overview page.